Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547084 | 0.85 | DPP4 (0.38) | MAPTCACNA1BAPBA1 | |
| SCHEMBL9547290 | 0.78 | MAPT (0.39) | MAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL8769211 | 0.75 | CASP1 (0.45) | MAPTCACNA1BAPBA1ALDH1A1CASP1 | |
| SCHEMBL9547229 | 0.72 | POLB (0.46) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9547154 | 0.71 | TSHR (0.33) | MAPTCACNA1BAPBA1 | |
| SCHEMBL9547277 | 0.71 | ZDHHC20 (0.38) | MAPTCACNA1BAPBA1 | |
| SCHEMBL9547244 | 0.71 | MAPT (0.41) | MAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL9482612 | 0.69 | CYP3A4 (0.39) | MAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL9547251 | 0.69 | MAPT (0.40) | MAPTCACNA1BAPBA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9547367 | 0.69 | MAPT (0.32) | MAPTCACNA1BAPBA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |